136 related articles for article (PubMed ID: 383291)
1. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
3. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
4. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
5. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
6. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
[TBL] [Abstract][Full Text] [Related]
7. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
Wan CW; Mak TW
Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
[TBL] [Abstract][Full Text] [Related]
8. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
[TBL] [Abstract][Full Text] [Related]
9. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
[TBL] [Abstract][Full Text] [Related]
10. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of 5-fluorodeoxyuridine plus cytosine arabinoside infusions in patients with solid tumors.
Cummings FJ; Hoovis ML; Calabresi P
Cancer Treat Rep; 1979 Aug; 63(8):1371-4. PubMed ID: 157808
[TBL] [Abstract][Full Text] [Related]
13. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
14. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Marsh JH; Kreis W; Barile B; Akerman S; Schulman P; Allen SL; DeMarco LC; Schuster MW; Budman DR
Cancer Chemother Pharmacol; 1993; 31(6):481-4. PubMed ID: 8453688
[TBL] [Abstract][Full Text] [Related]
15. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
Ohshima A; Yoshida K; Sato T; Miyazaki S; Yanagisawa M; Nakayama Y; Takahashi T; Mamiya S; Fukusima Y; Miura AB
Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
[TBL] [Abstract][Full Text] [Related]
17. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
[TBL] [Abstract][Full Text] [Related]
18. Ara-C metabolism: implications for drug resistance and drug interactions.
Chabner BA; Hande KR; Drake JC
Bull Cancer; 1979; 66(1):89-92. PubMed ID: 420952
[TBL] [Abstract][Full Text] [Related]
19. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
20. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
